Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rucaparib Camsylate,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Survivorship of women with advanced ovarian cancer has improved, primarily the result of 2 key agents, bevacizumab and Poly (ADP-ribose) polymerase inhibitors. In ATHENA trial, demonstrate the efficacy and safety of a third agent Rubraca (rucaparib) for ...
Product Name : Rubraca
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2022
Lead Product(s) : Rucaparib Camsylate,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Elevation Oncology and US Oncology Research Ink Collaboration in Support of Phase 2 CRESTONE Study
Details : Under this collaboration Elevation Oncology will utilize US Oncology Research Selected Trials for Accelerated Rollout program for patient enrollment in the registration-enabling Phase 2 CRESTONE study for patients with solid tumors of any origin that hav...
Product Name : MM-121
Product Type : Antibody
Upfront Cash : Undisclosed
September 30, 2020
Reset All
